Company Overview and News

 
Tri-Mode System banks on HiClicks to ride e-commerce wave

2018-10-16 theedgemarkets
Hew: We give you the freedom to shop anywhere in Japan, Taiwan, South Korea and the US.
4634 0078 8397 5267

 
Higher property sales seen to lift Tiong Nam’s 2QFY19 earnings

2018-08-29 theedgemarkets
Tiong Nam Logistics Holdings Bhd (Aug 28, RM1.01) Upgrade to buy with an unchanged target price (TP) of RM1.10: Tiong Nam Logistics Holdings Bhd’s core profit for the first quarter of financial year 2019 (1QFY19) of RM8.1 million accounted for 18.1% of our full-year forecast and 17.3% of consensus estimates. We consider the result within expectations as we expect 2QFY19 earnings will be lifted by higher property sales during the zero-rated goods and services tax (GST) period.
8397

 
Tiong Nam 1Q net profit jumps on growth in logistics and warehousing services

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): Tiong Nam Logistics Holdings Bhd’s first quarter net profit rose 7.1 times to RM4.86 million or 1.07 sen per share, from RM683,000 or 0.16 sen per share a year ago, on growth in its logistics and warehousing services segment and narrower losses in the investments segment.
8397

 
Tech: Muted interest in logistics counters

2018-07-04 theedgemarkets
ALIBABA Group opened an office in Bangsar South, Kuala Lumpur, last Monday — a reflection of the group’s commitment to Malaysia. While he was in town for the opening, executive chairman Jack Ma met Prime Minister Tun Dr Mahathir Mohamad in Putrajaya for an hour.
4634 0078 MYPRY 8397 BSMAF 5014 1818

 
Wong Engineering to expand via M&A

2018-07-02 theedgemarkets
KUALA LUMPUR: Little-known Kedah-based firm Wong Engineering Corp Bhd (WEC) has certainly caught investors off guard with its rapid earnings growth over the past two years.
8397

4
Tiong Nam Logistics unit buys land in JB

2018-06-06 thestar.com.my
KUALA LUMPUR: Tiong Nam Logistics Holdings Bhd 's subsidiary Medini Heritage Sdn Bhd has acquired 40.6 ha of vacant land from Prestij Sdn Bhd in Johor Bahru for RM40.21mil.
8397 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...